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Abstract: Homocystinuria is an inborn error of metabolism due to the deficiency in cystathionine
beta-synthase (CBS) enzyme activity. It leads to the elevation of both homocysteine and methionine
levels in the blood and urine. Consequently, this build-up could lead to several complications
such as nearsightedness, dislocated eye lenses, a variety of psychiatric and behavioral disorders,
as well as vascular system complications. The prevalence of homocystinuria is around 1/200,000
births worldwide. However, its prevalence in the Gulf region, notably Qatar, is exceptionally high
and reached 1:1800. To date, more than 191 pathogenic CBS mutations have been documented.
The majority of these mutations were identified in Caucasians of European ancestry, whereas only a few
mutations from African-Americans or Asians were reported. Approximately 87% of all CBS mutations
are missense and do not target the CBS catalytic site, but rather result in unstable misfolded proteins
lacking the normal biological function, designating them for degradation. The early detection of
homocystinuria along with low protein and methionine-restricted diet is the best treatment approach
for all types of homocystinuria patients. Yet, less than 50% of affected individuals show a significant
reduction in plasma homocysteine levels after treatment. Patients who fail to lower the elevated
homocysteine levels, through high protein-restricted diet or by B6 and folic acid supplements, are at
higher risk for cardiovascular diseases, neurodegenerative diseases, neural tube defects, and other
severe clinical complications. This review aims to examine the mutations spectrum of the CBS gene,
the disease management, as well as the current and potential treatment approaches with a greater
emphasis on studies reported in the Middle East and North Africa (MENA) region.
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1. Introduction
Inborn errors of metabolism represent a large group of genetic disorders that result from
an inherited deficiency or lack of proteins involved in metabolic pathways. The majority are defects of
single genes that code for enzymes, which catalyze essential biologically and biochemical reactions.
Although each specific inborn error of metabolism is rare, taken together, they represent a significant
source of congenital disabilities. For instance, it is estimated that a genetically caused inborn error of
metabolism occurs in 1/2500 births [1]. A prototypical example of an inborn error of metabolism is
homocystinuria due to CBS deficiency [2].
Classical homocystinuria (OMIM 236200) is an autosomal recessive disease and the most common
form of homocystinuria worldwide. It is an inborn error of metabolism with high clinical variability
resulting in a metabolic disorder due to deficiency in cystathionine beta-synthase CBS enzyme
activity (Figure 1). Consequently, an impaired CBS activity leads to the elevation of both the
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methionine and homocysteine levels in the blood and urine, leading to hyperhomocysteinemia,
homocystinuria, hypermethioninaemia, and hypocysteinaemia. In healthy adults, the concentration
of total homocysteine in plasma ranges from 5 to 15 µM; however, it reaches 200 µM in untreated
CBS deficient patients [3]. This build-up could lead to several complications such as nearsightedness
and dislocated eye lenses. In addition, the raised homocysteine levels could alter the intracellular
signaling and cause endoplasmic reticulum stress with endothelial dysfunction [4,5]. Consequently,
leading to thromboembolism, vascular, and other diseases [6]. Clinically, CBS deficient patients may
present with intellectual disability, a variety of psychiatric and behavioral disorders, skeletal and
ocular abnormalities, vaso-occlusive disease, as well as vascular system complications [7]. Affected
babies are healthy at birth, but may exhibit a failure to thrive during infancy and developmental
delay during the first years of life. To date, there is no cure for homocystinuria and the available
treatments target lowering the homocysteine level through betaine, folic acid, and pyridoxine (vitamin
B6) supplements. The main aim is to keep the plasma homocysteine as close to the normal range
as possible. However, a considerable fraction of affected patients is nonresponsive to pyridoxine
treatment. In addition, a methionine-restricted diet is not optimal, and poor compliance leads to serious
complications [8]. Therefore, currently the therapeutic approach for homocystinuria is shifted toward
stabilizing and rescuing the protein’s native structural conformations through chemical chaperones
and proteasome inhibitors. Furthermore, several studies are focusing on other approaches, such as
gene and enzyme replacement therapies that will be explained later in Section 6 (Current and potential
treatment approaches).
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reductase (MTHFR), hydrogen sulfide (H2S). 
Methionine is an essential sulfur-containing amino acid that is involved in the development and 
proper mammalian growth. Once the dietary proteins are ingested and methionine enters the cells, 
methionine adenosyltransferase (MAT) will catalyze the condensation of methionine with ATP and 
form S-adenosylmethionine (SAM), also known as AdoMet. SAM serves as a crucial methyl donor 
Figure 1. Homocysteine metabolism pathway. Methionine adenosyltransferase (MAT);
methyltransferase (MT); S-adenosylhomocysteinase hydrolase (SAHH); betaine-homocysteine
methyltransferase (BHMT); pyridoxal-phosphate (PLP); cystathionine gamma-lyase (CGL); methionine
synthase (MS); serine-hydroxymethyltransferase (SHMT); methyl-tetrahydrofolate-reductase (MTHFR),
hydrogen sulfide (H2S).
Methionine is an essential sulfur-containing amino acid that i i lved in the development and
proper mammalian growth. Once the dietary proteins are inge d ethio in enters the cells,
methionine ade osyltransferase (MAT) will catalyze the conde sation f methionine with ATP and form
S-adenosylmethionine (SAM), also known as AdoMet. SAM serves as a crucial methyl donor for various
methyltransferase reactions, including hormones biosynthesis and generating S-adenosylhomocysteine
(SAH). SAH is then reversibly hydrolyzed into adenosine and homocysteine through the action of
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S-adenosylhomocysteinase hydrolase (SAHH). Homocysteine is a nonproteinogenic toxic intermediary
amino acid residing at the intersections of several pathways. It can be remethylated through methionine
synthase (MS) or liver-specific betaine-homocysteine methyltransferase (BHMT), which requires betaine
as methyl donors. The other route of homocysteine is the transsulfuration pathway, where cystathionine
beta-synthase (CBS) irreversibly converts homocysteine to cysteine. It catalyzes the condensation of
homocysteine with serine and forms cystathionine, which is subsequently cleaved by cystathionine
gammalyase (CGL) into cysteine and 2-oxobutyrate. Cysteine can be further converted to taurine and
hydrogen sulfide (H2S).
Accordingly, the lack of CBS elevates the level of homocysteine and methionine and lowers
the concentrations of cystathionine and cysteine in the plasma of homocystinuria patients. It is
worth mentioning that both pathways require a particular member of the vitamin B family. For
instance, riboflavin (B2) serves as a cofactor for methyl-tetrahydrofolate-reductase, pyridoxine (B6) in
serine-hydroxymethyltransferase, CBS and CGL, folic acid (B9) and cobalamin (B12) in methionine
synthase. CBS regulates the flow of organic sulfur from methionine to the biosynthesis of all other
sulfur-containing compounds such as homocysteine, cysteine, and taurine and their metabolism.
Therefore, classical homocystinuria, due to a deficiency in CBS activity, is the most common inborn
error of sulfur amino acid metabolism. The prevalence of homocystinuria is around 1/200,000 births
worldwide. However, its prevalence in the Gulf region, notably Qatar, is exceptionally high and
reached 1:1800 [9].
CBS is a homotetrameric protein with each subunit composed of three structural domains [10,11]:
(i) A C-terminal regulatory domain containing the CBS domain tandem and the binding site for
the allosteric activator AdoMet (ii) a catalytic core, which is highly conserved and includes the
PLP (B6) binding site and; (iii) an N-terminal portion which acts as a heme-binding domain [11,12].
The C-terminal region consists of two CBS domains that are involved in hydrophobic regulatory
interactions and could partially shield the active site, thus exhibiting an auto-inhibitory function [13].
SAM binding to the CBS C-terminal domain induces a conformational change that leads to a higher
enzymatic activity [14]. This is achieved by eliminating the autoinhibition exerted by the regulatory
region, thus, facilitating the access of substrates to the catalytic pocket. In fact, Ereño-Orbea et al.
showed that SAM leads to progression of particular CBS mutants toward the activated state. To date,
more than 191 pathogenic CBS mutations have been documented. The majority of these mutations were
identified in Caucasians of European ancestry, whereas only few mutations from African-Americans or
Asians were reported [15]. Approximately 87% of all CBS mutations are missense and do not target
the CBS catalytic site, but rather result in unstable misfolded proteins lacking the normal biological
function, designating them for degradation [12]. In addition, a considerable fraction of CBS mutants
show impaired response to SAM binding as an allosteric activity modulator and protein stabilizer.
This review aims to examine the mutations spectrum of the CBS gene in homocystinuria patients with
a greater emphasis on those reported in the Middle East and North Africa (MENA) region.
2. The most Common CBS Reported Mutations Worldwide
For the last three decades, CBS inactivating mutations have been extensively studied in the context
of causing homocystinuria [16]. Overall, homocystinuria caused by CBS deficiency is considered
a relatively rare disease with an incidence rate varying from one in every 200,000 to 335,000 live
births. Table 1 summarizes the most common CBS mutations that were reported in different parts of
the world. Studies showed that CBS is common in some countries, including Ireland (1 in 65,000),
Germany (1 in 17,800), Norway (1 in 6400), and reached the highest prevalence in Qatar (1 in 1800) [17].
Homocystinuria is reported as an autosomal recessive disease, where the marriage of two CBS
carriers’ mutant genes could result in having children with homocystinuria. Furthermore, the high
consanguinity rate in the MENA community is considered an important factor that leads to an increase
in the prevalence of many metabolic disorders.
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Table 1. Cystathionine beta-synthase (CBS) mutations and clinical phenotypes of homocystinuria reported worldwide.
Country NucleotideChange Protein Change Exon Mutation Type Consanguinity
Pathogenicity and most Common
Associated Phenotype Phenotypes
Responsive to
Pyridoxine (Vitamin
B6) Treatment
Reference
Western Eurasians c.833T>C p.I278T 8 Missense No
Pathogenic-Ectopia lentis, Marphanoid
feature, mental retardation, idiopathic
infertility, severe vascular complications
Responsiveness [18]
Denmark Norway
Germany
Czech and Slovak
Republics
c.833T>C p.I278T 8 Missense -
Pathogenic-Ectopia lentis, Marphanoid
feature, mental retardation, idiopathic
infertility, severe vascular complications
Responsiveness [19,20]
Czech c.1105C>T p.R369C 10 Missense -
Patients do not have any clinical symptoms
at all. The late onset of symptoms, lack of
mental retardation, and connective tissue
involvement
Responsiveness [21]
Slovakia
526 G>A p.E176K 4 Missense No
Conflicting interpretations of pathogenicity.
Thoracic aortic aneurysm and aortic
dissection. Cardiovascular phenotype
Nonresponsiveness [22]
1226 G>A p.W409X 12 Nonsense No - Nonresponsiveness
Netherland
c.833T>C p.I278T 8 Missense No
Pathogenic-Ectopia lentis, Marphanoid
feature, mental retardation, idiopathic
infertility, severe vascular complications
Responsiveness [12,19]
c.539 T>C p.V180A 5 Missense No - - [12]
c.1330G>A p.D444N 12 Missense No Mild -
Ireland
c.919 G>A p.G307S 8 Missense - Pathogenic-Cardiovascular phenotype Nonresponsiveness [23–25]
c.306 G>C p.K102N 2 Missense No
Likely pathogenic-Neurogenic bladder or
bowel signs, developmental delay, mental
retardation
Responsiveness [26]
Italy
c.146 C>T p.P49L 1 Missense No Pathogenic, VUS Cardiovascular phenotype Responsiveness [27]
c.172 C>T p.R58W 1 Missense No
Mild mental retardation with EEG
anomalies, osteoporosis, malar flush, and
ultrasound evidence of arterial disease
Nonresponsiveness [28]
c.262 C>T p.P88S 2 Missense - Pathogenic-Zonular pulverulent cataractphenotype - [29]
c.469G<C p.A157P 4 Missense No
Pathogenic-Pectus escavatum, Tricuspid
valve prolapse, Kyphoscoliosis,
Iridodonesis, Mild elbow valgus
- [30]
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Table 1. Cont.
Country NucleotideChange Protein Change Exon Mutation Type Consanguinity
Pathogenicity and most Common
Associated Phenotype Phenotypes
Responsive to
Pyridoxine (Vitamin
B6) Treatment
Reference
Spain
c.869 C>T p.P290L 8 Missense No Hermansky Pudlak syndrome 2 Responsiveness [29]
c.572C>T p.T191M 5 Missense No Pathogenic Nonresponsiveness [31]
c.833T<G p.I278S 8 Missense No Pathogenic Responsiveness [32]
Portugal c.572C>T p.T191M 5 Missense No Pathogenic Nonresponsiveness [31]
Venezuela c.700G>A p.D234N 8 Missense Yes Pathogenic-Skeletal and ocularabnormalities Nonresponsiveness [33]
France
1150 A>G p.K384E 11 Missense No Pathogenic Responsiveness [34]
1616 T>C p.L539S 16 Missense No Pathogenic Responsiveness
UK
c.374G>A p.R125Q 3 Missense No PathogenicCardiovascular phenotype - [35]
c.430G>A p.E144K 3 Missense No PathogenicCardiovascular phenotype - [35]
c.833T>C p.I278T 8 Missense No
Pathogenic-Ectopia lentis, Marphanoid
feature, mental retardation, idiopathic
infertility, severe vascular complications
Responsiveness [35]
c.919G>A p.G307S 8 Missense No Pathogenic-Cardiovascular phenotype Nonresponsiveness [25,35]
USA
c.341C>T p.A114V 3 Missense No - - [35]
c.374G>A p.R125Q 3 Missense No Pathogenic-Cardiovascular phenotype Nonresponsiveness [35,36]
c.785C>T p.T262M 7 Missense No Pathogenic-Thromboembolic episodes,mental retardation Nonresponsiveness [35,36]
c.797G>A p.R266K 7 Missense No - Responsiveness [35]
c.833T>C p.I278T 8 Missense No Pathogenic-Severe vascular complications Responsiveness [35]
c.919G>A p.G307S 8 Missense No Pathogenic-Cardiovascular phenotype Nonresponsiveness [25,35]
g.13217A>C (del ex 12) Intron 11 Deletion No - - [35]
c.1330G>A p.D444N 12 Missense No Pathogenic-Psychomotoric retardation andmarfanoid features
Partially
pyridoxine-responsive [35,37]
India c.518delTGA p.M173del 4 Deletion No Pathogenic - [32]
Argentina
c.676G<A p.A226T 6 Missense No Mild-Hypertrophic cardiomyopathy Responsiveness [25,32]
c.962A<T p.D321V 9 Missense No Pathogenic-Crouzon syndrome - [32,38]
c.1336G<T p. A446S 12 Missense No Mild-lens dislocation Responsiveness [32]
Australia c.833T>C p.I278T 8 Missense No
Pathogenic-Ectopia lentis, Marphanoid
feature, mental retardation, idiopathic
infertility, severe vascular complications
Responsiveness [39]
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The CBS gene is located on the long arm of chromosome 21 with 191 variants having been
described [40] (Figure 2). The most frequent pathogenic and reported mutations in different countries
around the world are p.G307S (31%), and p.I278T (24%) [41,42]. The p.G307S mutation is the most
prevalent CBS deficiency mutation in Ireland and Australia [6,23]. It is located on exon 8 of CBS
gene, where guanine at position 919 is replaced by adenine nucleotide (c.919G>A). This change
leads to glycine to serine substitution at position 307. Homozygous patients are severely affected
with minimal to nonresponse to pyridoxine (B6) treatment [28,43]. Studies showed that p.G307S
mutation is also frequently detected in homocystinuria patients of Celtic descent [43]. Using molecular
dynamic simulations, a study showed that p.G307S mutation impaired the catalytic function of the
CBS enzyme by preventing the tyrosine residue at position 308 to assume the proper conformational
folding. This state is required for forming the pyridoxal–cystathionine intermediate. Additionally,
results showed CBS with p.G307S mutation is stable, but inactive, and hence does not respond either
to chaperone-based therapy nor pyridoxine treatment [24].
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Figure 2. CBS gene structure with associated mutations. Exons are represented by white numbered
boxes and the CBS variants are color coded by mutation type.
Similarly, the p.I278T mutation affects the catalytic domain of the CBS enzyme [16]. Yet, confers
responsiveness to pyridoxine tre tment [6]. It is considered the most prevalent mutation worldwide,
particularly in homoc stinuria p tients of nonCelt c d scent [43]. The p.1278T mutation was first
identified in a pyridoxine-responsiv patie t with mild clinical manifestation [44]. Thi mutation
results from incorrect excision of a 68-bp repeat polymorphism within the CBS gene [45]. Consequently,
it leads to the substitution of thymine with a cytosine at position 833 (c.883T>C) of exon 8. This
change leads to isoleucine to threonine substitution at position 278. The pathogenicity of p.I278T CBS
mutation was shown to be due to the lack of catalytic activity in a bacterial and yeast expression system.
For instance, using the yeast S. cerevisiae as an in vitro model showed that p.I278T has only 2.4% of
the human wildtype CBS enzymatic activity and failed to complement the growth phenotype [46].
Consequently, patients with p.I278T usually had vasc lar and conne tive tissue defects [47]. Other
clinical complications of defective CBS enzyme include dislocation of the ocular lenses (ectopia lentis),
mental retardation, osteoporosis, and thromboembolism.
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3. The Prevalence of CBS and Associated Mutations in the MENA Region
The establishment of newborn screening programs has successfully decreased the prevalence
of homocystinuria and other aminoacidopathies. Yet, the majority of these disorders arise due to
consanguineous marriages [48]. The consanguinity rate reached 40% among first cousins in the Middle
East and up to 60% in intermarriages between relatives. Therefore, the incidence of genetic disorders,
including homocystinuria, has increased. To date, scarce studies reported the incidence rate of CBS
in the MENA region. For instance, the reported incidence in Oman is one in approximately 128,200
births [49], while in Saudi Arabia, the incidence of homocystinuria is two in 100,000 live births [50].
Additionally, in a Kuwait-based study, the frequency of CBS mutation among intellectually disabled
patients was 0.23% [51].
In Qatar, the homozygous mutation c.1006C>T (p.R336C), which is found on exon 9 of the
CBS gene (Figure 2), a missense mutation in which arginine is replaced by cysteine, consequently
resulting in a severe vitamin B6 nonresponsive phenotype [9]. The prevalence of this unique mutation
in Qatar is approximately 1:1800 births, where ~6% of the population has a heterozygous p.R336C
mutation with an allele frequency of 1% [52]. The p.R336C mutation was first reported in a patient of
English descent [28]. Subsequently, it was observed in Australia [53], the Iberian peninsula [54], and
recently in Korea [55]. The in vitro expression studies, as well as the enzymatic measurements, along
with the clinical symptoms of the patients suffering from this mutation, showed that the mutation
eliminated the CBS enzymatic activity. The p.R336C mutation appears to be recurrent in different
independent populations. Thus, the correlation between this mutation in the Qatari population
and other populations could not be established. Treating the Qatari homocystinuria patients with
traditional therapy has been very challenging because the strict low protein content diet is difficult to
maintain, and the p.R336C mutation is pyridoxine nonresponsive. Therefore, this disease imposes
a financial and clinical burden on the population in Qatar that necessitates an urgent need for the
development of an adequate therapy [52,56].
On the other hand, one Qatari patient had a homozygous mutation c.700G>A (p.D234N), which
was previously described in Puerto Rican [12] and Venezuelan patients [57]. Similar to c.1006C>T
mutation, this mutation includes a hypermutable CpG dinucleotide (transition from guanine to
adenine) [58]. According to El-said et al., this mutation has a high chance of recurrence in the Qatari
population [59]. However, according to the clinical observation and the genotyping of all Qatari patients
suffering from homocystinuria predict the absence of CBS enzymatic activity and nonresponsiveness to
vitamin B6 supplements [59]. Although homocystinuria is considered the most prevalent monogenic
disease in Qatar, early detection has improved the prevention of some complications, including mental
retardation, ectopia lentis, and thromboembolic events [60].
In Saudi Arabia, patients suffering from homocystinuria expressed the cardinal biochemical
features of homocystinuria. In addition, most of the clinical manifestations reported due to
homocystinuria in the Saudi Arabian cohort were related to the ophthalmological, musculoskeletal,
vascular, and nervous systems complications [7,27,61]. For instance, some Saudi patients, who suffered
from white matter abnormalities, were also reported with homocystinuria. However, Zaidi et al.,
reported a case of Legg–Calv´e–Perthes disease, a previously unknown complication in homocystinuria,
which was observed in one patient suffering from a novel p.W323X mutation in the CBS gene [62].
Zaidi et al., explained the occurrence of Legg–Calv´e–Perthes disease as vascular thromboembolism
due to the persistently elevated homocysteine leading to vascular necrosis of the femoral head in
their patients. This novel mutation is considered the predominant mutation in Saudi Arabia and
was reported in 10 Saudi families. This could be due to the high consanguinity marriage causing
homozygosity of the recessive alleles and the expression of disease phenotype in patients. Similarly,
two recurrent mutations, c.457G>A (p.G153R) and c.1006C>T (p.A336C), were reported in two Saudi
families and described previously [28,53,63].
In Palestinian Arab homocystinuria patients, six different CBS mutations, c.304A>C, c.833T>C,
c.785C>G, g.1627del19, IVS17 (g18327del 5), and IVS4 (g6643del 29), have been reported in this highly
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inbred population [64]. These mutations were novel and were not reported in the neighboring regions.
However, patients living in the same villages carry the same genetic alterations, thus indicating
a founder effect. Despite the adjacent geographic region of Palestine, Saudi, Palestinian Arabs have
a different spectrum of the CBS gene mutations. The narrow geographic spread of these mutations
suggests that they arose over the past few generations [64].
In Sudan, a CBS mutation c.770C>T (p.T257M or pThr257Met) was reported. Interestingly,
the same mutation was also reported in Spanish and Italian families (15,17). The pThr257Met mutation
was shown to have <1% of the CBS enzyme activity and conferred nonresponsiveness to pyridoxine
treatment. Table 2 summarizes the identified CBS mutations that were reported in different countries
of the MENA region.
4. Recent Novel CBS Mutations
Recently, two novel mutations, a missense change (c.467T>C; p.L156P) and an in-frame deletion
(c.808_810del; p.E270del) were reported in Pakistani children [65]. The mutations were identified using
Sanger sequencing and resulted in hyperhomocysteinemia and lens dislocation in three patients from
different families. In addition, eight novel mutations in CBS were identified in Chinese patients with
classical homocystinuria. None of these missense mutations were reported in other regions previously.
Moreover, the effect of these mutations on CBS gene expression, CBS protein expression, stability,
and activity is not investigated yet. However, Li et al., with the use of the PolyPhen-2 prediction
software, indicated that the p.T236A and p.L230G are probably damaging while the p.L72I is a benign
mutation. On the other hand, the SIFT prediction software indicated that the p.T236A and p.L230G are
damaging, while the p.L72I is a tolerated mutation (17). Similarly, a total of 35 samples were obtained
from Brazilian patients with a biochemically confirmed diagnosis of classical homocystinuria [42].
Eight novel mutations [c.2T>C, c.209+1delG, c.284T>C, c.329A>T, c.444delG, c.864_868delGAG,
c.989_991delAGG, and c.1223+5G>T] were found. It is worth mentioning that there was high
variability in the genotypes, and most of the patients in this study were pyridoxine nonresponsive.
Generally, the treatment of homocystinuria patients with varying missense mutations is based on
a combined high-dose of cofactors of homocysteine metabolism and a life-long methionine-restricted
diet. Yet, less than 50% of affected individuals show a significant reduction in plasma homocysteine
levels after treatment [7,66].
5. Clinical Diagnosis and Disease Detection
Clinically, patients with classic homocystinuria exhibit numerous manifestations during infancy
because homocysteine disrupts the development of many organ systems. These include Marfanoid
habitus, pectus exavatum (curved-in sternum), pectus carinatum (protruding sternum), genu valgum,
where knees are angled toward each other, and many other skeletal deformities [67,68]. In addition,
ectopia lentis (dislocation of the lens) can lead to nearsightedness and blurred vision. Homocystinuria
was first discovered in 1962 in Northern Ireland, where the patients had mental retardation [69]. Shortly
after that, CBS enzyme deficiency was demonstrated as the causative factor for this abnormality [70].
Significant progress has been achieved in diagnosing homocystinuria since the time of its discovery.
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Table 2. CBS mutations and clinical phenotypes of homocystinuria in Arab countries.
Country NucleotideChange Protein Change Exon Mutation Type Consanguinity
Pathogenicity and most Common
Associated Phenotype
Phenotypes
Responsive to
Pyridoxine (Vitamin
B6) Treatment
Reference
Qatar
c.1006C > T p.R336C 11 Missense
- Pathogenic-Hyperhomocystimia,
Disproportionate tall stature, Lens
luxation, Thromboembolism,
Intellectual disability Seizures
Nonresponsiveness
[9,52,59,67]
Yes (98.4% of
the patients) [68]
Yes (84% of the
patients) [71]
c.700G>A p.D234N 8 Missense Yes Pathogenic-Skeletal and ocularabnormalities Nonresponsiveness
c.1039G>A p.G347S 9 Missense - - Not known
Saudi Arabia
c.969G>A p.Trp323X 9 Novel nonsensemutation Yes
Pathogenic-a truncation of the CBS
protein and results in the complete
loss of the CBS enzyme activity.
Elevated plasma levels of
homocysteine and methionine
Nonresponsiveness [42,72]
c.1006C>T p.R336C 11 Missense Yes
Pathogenic-Hyperhomocystimia,
Disproportionate tall stature, Lens
luxation, Thromboembolism,
Intellectual disability Seizures
Nonresponsiveness [72]
c.457G>A p.G153R 4 Missense Yes Likely pathogenic - [72]
Oman 844ins68 - 8 Insertion - Aneurysmal subarachnoidhemorrhage - [73]
Lebanon c.1152 G>C p.K384N 11 Missense - - - Unpublisheddata
Sudan c.770C>T p.T257M 7 Missense Yes Pathogenic due to complete loss ofCBS enzyme activity Nonresponsiveness [55,72]
Palestinian Arab
c.304A>C p.K102Q 2 Missense
Yes
Likely benign-Ectopia Lentis,
Marphanoid features,
Thromboembolic episodes
Variable
[64]
c.833T>C p.I278T 8 Missense
Pathogenic-Ectopia lentis,
Marphanoid feature, mental
retardation, idiopathic infertility
Responsive
c.785C>G p.T262R 7 Missense Pathogenic-Thromboembolicepisodes, mental retardation -
g.1627del 19
addition of
non-coded 17
amino acids
16 Deletion/Frameshift Pathogenic -
IVS17
(g18327del 5). - 16 Deletion
Pathogenic-Ectopia lentis, mental
retardation -
IVS4 (g6643del
29)
29 bp deletion (exon
5 skipping) 5 Deletion Pathogenic -
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Table 2. Cont.
Country NucleotideChange Protein Change Exon Mutation Type Consanguinity
Pathogenicity and most Common
Associated Phenotype
Phenotypes
Responsive to
Pyridoxine (Vitamin
B6) Treatment
Reference
Pakistan
c.467T>C p.L156P 7 Missense Yes
Pathogenic-Developmental and
Neurological problems. Myopia
and lens dislocation
- [65]
c.808_810del p.E270del 10 In-framedeletion Yes
Pathogenic
Developmental and Neurological
problems. Glaucoma and
subluxated lens.
-
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Although the management and clinical diagnosis of homocystinuria could differ from country to
country, this disorder is mostly diagnosed based on the patient clinical features and routine metabolic
testing. The analysis of plasma and urine amino acid will show a frequent elevation of both methionine
(>50 µmol/L) and homocysteine (>100 µmol/L). Some Arab countries have implemented the utilization
of several molecular diagnostic techniques, including mass spectrometry (MS), high-pressure liquid
phase chromatography (HPLC), and sequencing techniques such as Sanger and next-generation
sequencing [74]. In addition, molecular genetic testing and neonatal screening programs have been
incorporated in the disease screening system as early intervention could facilitate effective treatment.
Yet, this genetic monitoring requires high-throughput, reliable, and rapid methods to extract DNA and
subsequently analyze the mutations, which may not be universally available and could be challenging
to implement [52]. Additionally, some technologies are currently emerging in rapid metabolite-based
disease biomarker screening. For instance, a recent study identified paper spray ionization mass
spectrometry (PSI-MS) for analyzing metabolic biomarkers associated with children disorder [75]. As
mass spectrometry is a recognized gold standard technique for an inborn error of metabolism study,
PSI-MS shows great potential for point-of-care clinical applications. Additionally, PSI-MS could be
a great tool for early stage rapid biomarker discovery for Homocystinuria. In addition, other assays
depend on measuring the CBS activity through a fluorescent probe. For instance, the assay utilizes
homocysteine and cysteine as a substrate to produce hydrogen sulfide. The latter will react with a probe
containing azido-functional group and consequently yielding a fluorescent amino group. Previously,
an elevated level of methionine was detected through screening of homocystinuria biochemical
metabolites. However, this method had poor sensitivity. In addition, it was technically difficult to
quantify homocysteine in dried blood spots (DBS). Due to the high prevalence of homocystinuria
and, because early detection could significantly benefit children, a dual strategy screening has been
developed in Qatar to screen all newborns with homocystinuria [58]. The national biochemical and
molecular newborn screening (NBS) program has been established in Qatar in 2006, which includes
both biochemical and molecular screening approaches. These include combining HPLC with tandem
mass spectrometry to quantify the total homocysteine in DBS. Additionally, rapid high-throughput
genetic screening has been introduced to detect CBS gene mutations that are identified in Qatari
population including p.R336C and p.D234N. This was achieved by utilizing an automated 96-well plate
DNA extraction method followed by individual PCR-based fluorogenic TaqMan probe assays [58].
Apart from the disease management and complications that may arise during the patient’s lifespan,
parents should be aware that there is a 25% chance of recurrence risk in a subsequent pregnancy.
Additionally, there is an increased likelihood that a child with homocystinuria may have siblings who
are potential carriers [41]. Therefore, genetic counseling is recommended for prospective parents,
especially those with a history of homocystinuria in the family. Moreover, prenatal diagnosis can
be implemented and achieved through culturing the chorionic villi and amniotic cells to test for the
presence of CBS enzyme [76].
6. Current and Potential Treatment Approaches
The early detection of homocystinuria along low protein and methionine restricted diet is the
best treatment approach for all types of homocystinuria patients [68]. Referring to the homocystinuria
metabolism pathway (Figure 1), the administration of folic acid and pyridoxine is also considered as
an effective therapy, especially in pyridoxine-responsive patients, as these supplements have shown to
enhance the CBS enzyme residual activity in more than half of the patients [77]. Yet, they were not
effective in patients with B6 nonresponsive mutations such as the p.R336C [58]. Although significant
advances were made toward curing homocystinuria and protein misfolding, yet, there are no curative
treatments for this disease. Protein misfolding and its accumulation are the upstream events in the
pathological cascade. Thus, stabilizing and rescuing the protein’s native structural conformations is
a targeted therapeutic approach.
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Recently, chaperones have been recognized as effective molecules in reducing the accumulation of
misfolded proteins. Accordingly, minimizing their downstream pathological consequences. Several
chemical chaperones are receiving attention as possible treatments for many misfolded protein
mutations. For instance, the administration of 2% of the trehalose solution orally increased the stability
of the huntingtin containing protein and improved the motor dysfunction in a mouse model [78].
Randomized clinical trials proved that an FDA-approved Buphenyl, used for treating urea cycle
disorders, causes substantial stimulation of chloride transport in homozygous patients for F508 CFTR.
Thus, it is a viable therapeutic approach for cystic fibrosis patients [79].
In regards to CBS, Kopecka et al. studied in vitro the effect of selected chaperones including
δ-aminolevulinic acid (δ-ALA) and three osmolytes (taurine, betaine, and glycerol) on 27 different CBS
mutants. Of which, 14 mutants responded by at least 30% increase in the enzymatic activity, and four
mutants showed an increased formation of CBS tetramers, without an increase in the CBS activity [80].
For instance, PBA and TUDCA are FDA approved chemical chaperones used for urea cycle disorders
and biliary cirrhosis treatment, respectively [81]. Furthermore, studies showed that PBA attenuates
the endoplasmic reticulum (ER) stress and acts as an ammonia scavenger in urea cycle disorders [82].
Similarly, TUDCA has been shown to mitigate the ER stress and have an anti-apoptotic and antioxidant
activity [83].
Another potential chemical chaperone is betaine, which uses an alternative pathway to convert
homocysteine into methionine, and was reported to be effective in pyridoxine nonresponsive
patients [84]. In an attempt to rescue the functional defect of the p.R336C CBS mutation, a study
was conducted using knock-in p.R336C mutation in HEK293T cell line [9]. Cells were treated with
different types of chaperones (betaine, glycerol, sorbitol, and proline) at different concentrations.
Interestingly, betaine was able to restore the structural defect of the p.R336C protein in vivo, but not
the activity of the p.R336C mutation. Various treatment approaches, such as chemical chaperones [9],
CBS enzyme replacement therapy, and gene therapy [85] could be promising alternative treatments for
homocystinuria patients. Additional treatment strategies including the administration of proteasome
inhibitors or protein stabilizing drugs to prevent early degradation of mutated CBS protein. For example,
a recent report showed that proteasome inhibitors rescued the phenotype in p.I278T and p.S466L
mutant mice [86]. Furthermore, it was documented that bortezomib was able to restore both the growth
and CBS activity in p.I278T mutant yeast and mice [87]. Other potential chemical chaperones include
tauroursodeoxycholic acid (TUDCA), sodium 4-phenylbutyrate (PBA), urea derivatives chemical
chaperones such as trimethylamine oxide (TMAO), amino acid derivatives chemical chaperones such
as glycine, polyols chemical chaperones such as glycerol and sorbitol, mannitol, maltose, phenyl
butyric acid. Additionally, the use of aminothiols, such as cysteamine, holds potential clinical promise
to target arginine to cysteine mutations of different genetic disorders [88]. It is worth mentioning
that SAM analogs are also considered pharmacological chaperones and kinetic stabilizers that could
prevent the misfolding and rapid degradation of mutant CBS protein [89]. Studies demonstrated that
CBS tetramer is stabilized by SAM binding to a site different from the allosteric site responsible for
activation, and presented natural analogues that could stabilize CBS tetramer without interfering with
allosteric activation. Thus, rescuing the CBS activity in homocystinuria patients [89,90]. Yet, some
mutations, such as R125Q, E176K, P422L, and S466L, are SAM-nonresponsive mutants [90].
Shifting to in vivo models, a study previously described the development of a genetically
engineered mouse that expresses the p.R336C human CBS protein as its only source of CBS (Tg-R336C
Cbs-/-) [91]. As expected, these mice have extreme elevation in both serum total homocystinuria
and liver total homocystinuria compared to control transgenic mice. However, the administration of
bortezomib showed a complete rescue of CBS activity in these mice. The creation of such an in vivo
system to modulate plasma homocysteine would be useful in the study of homocysteine-related
diseases and finding novel therapeutic approaches for CBS deficiency. For instance, a study used
a minicircle-based naked DNA gene therapy technique to treat CBS deficient mice (Tg-I278T Cbs-/-) [92].
Following the injection of mice with the DNA-minicircle vector, results showed a significant decrease
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in serum total homocysteine level with a 34-fold increase in liver CBS activity. Therefore, the study
suggested that minicircle-based gene therapy could be a potential treatment for CBS deficiency. Another
promising approach is the enzyme replacement therapy. It involves intravenous infusions to correct
the deficiency or absence of an enzyme in the body. This approach was reported to be successful
in lysosomal storage diseases such as Gaucher disease, Fabry disease, as well as severe combined
immunodeficiency [86]. However, the use of enzyme replacement therapy to treat homocystinuria
due to CBS deficiency is not well addressed. Therefore, a recent study aimed to address the core
enzyme deficiency through the long-term administration of PEG-CBS [8]. Results showed that enzyme
replacement therapy significantly reduced the plasma homocysteine concentration and normalized
plasma cysteine for up to nine months of treatment. The metabolic and biochemical balance was restored
and improved in the kidney, liver, and brain of the CBS deficient mice (Tg-I278T Cbs-/-). Therefore,
enzyme replacement therapy has the potential to successfully correct the clinical manifestations in
homocystinuria patients and improve their life quality.
7. Conclusions
Homocystinuria is a monogenic disease caused by a deficiency in the activity of the CBS enzyme.
This study highlighted the necessity for further epidemiological studies in Arab countries, especially
in areas with high prevalence of consanguineous marriage. High consanguinity rate in the MENA
community is considered a factor that could also increase the prevalence of many metabolic disorders
including homocystinuria. Therefore, public health strategies should be implemented to increase
public understanding and awareness of the consequent genetic risks of consanguineous marriages. In
addition, screening programs should be applied in all Arab nations to facilitate its early detection and
consequent treatment. Although significant advances have been made toward curing homocystinuria,
yet, there are no curative treatments for this disease. Chemical chaperones and protein stabilizers
are considered potential therapeutic approaches for stabilizing and rescuing the protein’s native
conformations. Thus, restoring the CBS enzyme activity.
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